Concerns about an association between glucagon-like peptide-1 (GLP-1) receptor agonists, which are used for treatment of type 2 diabetes and for weight loss, and suicidality were raised following case reports submitted to the US Food and Drug Administration (and the European Medicines Agency.1,2 In this issue of JAMA Internal Medicine, 2 articles using very different study designs report data on the risk of GLP-1 receptor agonist initiation and adverse mental health outcomes. While both studies are reassuring, neither fully answers the question of whether these drugs are safe in those with preexisting mental health problems.